Richard Elion1, Megan Coleman. 1. aGeorge Washington University School of Medicine bWhitman Walker Health, Washington, District of Columbia, USA.
Abstract
PURPOSE OF REVIEW: This article describes the use of tenofovir/emtricitabine (Truvada) as prevention for exposure to HIV [preexposure prophylaxis (PrEP)] infection in the USA. The use of PrEP and the challenges of implementation are very instructive as other countries adopt this intervention and it becomes a fundamental part of worldwide efforts for HIV prevention and much can be learned from the first 3 years in the USA. RECENT FINDINGS: Randomized trials and demonstration projects have shown the benefits of PrEP for men and women who are at risk for HIV. Numerous studies have showed that the level of prevention is excellent when the drug is taken at least four times weekly, once adequate levels are obtained. However, adherence remains a critical issue as well as tailoring delivery models for specific populations. Six recent studies are discussed, that support excellent efficacy and significantly support PrEP as a means of prevention. These projects have shown high acceptance of PrEP with excellent adherence by individuals demonstrated by those at risk remaining free of HIV over extended periods of time. SUMMARY: The USA faces three significant challenges in scaling up PrEP. The first challenge in implementation in the USA is to get individuals to recognize the actual risks that their behaviors represent and to engage with providers to address these issues. The second challenge is getting a population of providers to recognize the exact same issues and offer PrEP in a compassionate, nonjudgmental fashion. The third challenge is identifying the set of providers and locations to scale-up the response in a timely, cost-effective fashion.
PURPOSE OF REVIEW: This article describes the use of tenofovir/emtricitabine (Truvada) as prevention for exposure to HIV [preexposure prophylaxis (PrEP)] infection in the USA. The use of PrEP and the challenges of implementation are very instructive as other countries adopt this intervention and it becomes a fundamental part of worldwide efforts for HIV prevention and much can be learned from the first 3 years in the USA. RECENT FINDINGS: Randomized trials and demonstration projects have shown the benefits of PrEP for men and women who are at risk for HIV. Numerous studies have showed that the level of prevention is excellent when the drug is taken at least four times weekly, once adequate levels are obtained. However, adherence remains a critical issue as well as tailoring delivery models for specific populations. Six recent studies are discussed, that support excellent efficacy and significantly support PrEP as a means of prevention. These projects have shown high acceptance of PrEP with excellent adherence by individuals demonstrated by those at risk remaining free of HIV over extended periods of time. SUMMARY: The USA faces three significant challenges in scaling up PrEP. The first challenge in implementation in the USA is to get individuals to recognize the actual risks that their behaviors represent and to engage with providers to address these issues. The second challenge is getting a population of providers to recognize the exact same issues and offer PrEP in a compassionate, nonjudgmental fashion. The third challenge is identifying the set of providers and locations to scale-up the response in a timely, cost-effective fashion.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Spencer Lieb; Stephen J Fallon; Samuel R Friedman; Daniel R Thompson; Gary J Gates; Thomas M Liberti; Robert M Malow Journal: Public Health Rep Date: 2011 Jan-Feb Impact factor: 2.792
Authors: Y Omar Whiteside; Tammy Harris; Christopher Scanlon; Stephen Clarkson; Wayne Duffus Journal: AIDS Patient Care STDS Date: 2011-04-06 Impact factor: 5.078
Authors: Douglas S Krakower; Matthew J Mimiaga; Joshua G Rosenberger; David S Novak; Jennifer A Mitty; Jaclyn M White; Kenneth H Mayer Journal: PLoS One Date: 2012-03-28 Impact factor: 3.240
Authors: David H Altreuter; Ameya R Kirtane; Tyler Grant; Cecilia Kruger; Giovanni Traverso; Andrew M Bellinger Journal: Expert Opin Drug Deliv Date: 2018-11-13 Impact factor: 6.648
Authors: Rachel K Scott; Shawnika J Hull; Jim C Huang; Megan Coleman; Peggy Ye; Pam Lotke; Jason Beverley; Patricia Moriarty; Dhikshitha Balaji; Allison Ward; Jennifer Holiday; Ashley R Brant; Martha Cameron; Rick Elion; Adam Visconti Journal: Arch Sex Behav Date: 2022-05-27
Authors: Brandon D L Marshall; William C Goedel; Maximilian R F King; Alyson Singleton; David P Durham; Philip A Chan; Jeffrey P Townsend; Alison P Galvani Journal: Lancet HIV Date: 2018-06-13 Impact factor: 12.767
Authors: Kshitij Wagh; Michael S Seaman; Marshall Zingg; Tomas Fitzsimons; Dan H Barouch; Dennis R Burton; Mark Connors; David D Ho; John R Mascola; Michel C Nussenzweig; Jeffrey Ravetch; Rajeev Gautam; Malcolm A Martin; David C Montefiori; Bette Korber Journal: PLoS Pathog Date: 2018-03-05 Impact factor: 7.464
Authors: K Rivet Amico; Jessica Miller; Christopher Balthazar; Pedro Alonso Serrano; Jennifer Brothers; Sarah Zollweg; Sybil Hosek Journal: AIDS Behav Date: 2019-07